You are here: Home: Audio Program Guide: BCU 3 | 2008 Audio: BCU 3 | 2008
 
  Go to interview with Daniel F Hayes, MD
Go to interview with John F Forbes, MD
Go to interview with Julie R Gralow, MD
Go to interview with John F R Robertson, MB,ChB, BSc, MD
Go toTumor Panel Discussion
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Hayes, MD Daniel F Hayes, MD
Professor of Internal Medicine
Clinical Director, Breast Oncology Program
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
  
  Click here to download the entire interview  
Track 1 Musculoskeletal side effects associated with hormonal therapy
Track 2 Randomized trial evaluating secondary effects with letrozole versus exemestane
Track 3 Arthritis associated with matrix metalloproteinase inhibitors
Track 4 Differential potency of letrozole or anastrozole versus exemestane
Track 5 Efficacy of chemotherapy according to ER and HER2 status
Track 6 CALGB-9344: Efficacy of adjuvant paclitaxel according to ER and HER2 status in node-positive disease

Track 7 Upcoming analyses of HER2 and ER status in CALGB-9344
Track 8 Clinical role of the Oncotype DX™ assay for patients with hormone receptor-positive, node-negative breast cancer
Track 9 Predictive value of the Oncotype DX assay for patients with hormone receptor-positive, node-positive breast cancer
Track 10 Clinical use of adjuvant anthracyclines
Track 11 Oncotype DX results and the selection of an adjuvant chemotherapy regimen
Track 12 Clinical use of the Oncotype DX assay for patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer
Track 13 Case discussion: A patient with HER2-positive (IHC 3+) early breast cancer and a low Oncotype DX recurrence score
Track 14 Measurement of circulating tumor cells (CTCs) in the blood
Track 15 Prognostic and predictive utility of CTCs in metastatic breast cancer
Track 16 SWOG-S0500: A Phase III trial of treatment decision-making based on CTCs in women with metastatic disease
     
Forbes, MD John F Forbes, MD
Professor, University of Newcastle
Director, Department of Surgical Oncology
Calvary Mater Newcastle Hospital
Newcastle, New South Wales
Australia
  
  Click here to download the entire interview  
Track 1 Long-term (100-month) follow-up data from the ATAC trial
Track 2 Carryover effects associated with hormonal therapy
Track 3 Endometrial cancer rates among women receiving hormonal therapy
Track 4 Reduction in breast cancer events with anastrozole versus tamoxifen in the ATAC trial
Track 5 ATAC trial: Overall and breast cancer mortality
Track 6 Overall versus disease-free survival as clinically meaningful endpoints in clinical trials
Track 7 ATLAS trial: Five versus 10 years of adjuvant tamoxifen

Track 8 Geographical differences in the efficacy of cancer treatments
Track 9 LATER trial: A randomized study of letrozole versus placebo for postmenopausal women who completed five years of adjuvant hormonal therapy at least one year ago
Track 10 Musculoskeletal side effects in the ATAC trial
Track 11 ATAC trial: Risk of bone fractures
Track 12 IBIS-2 prevention trial of anastrozole versus placebo for postmenopausal women at increased risk of breast cancer: Bone subprotocol
Track 13 Long-term bone safety data from the ATAC trial
     
Gralow, Md Julie R Gralow, MD
Associate Professor, Medical Oncology
University of Washington and Fred Hutchinson Cancer Research Center
Director, Breast Medical Oncology
Seattle Cancer Care Alliance/University of Washington
Seattle, Washington
  
  Click here to download the entire interview  
Track 1 Clinical algorithm for the treatment of metastatic breast cancer
Track 2 Combination regimens in the treatment of metastatic breast cancer
Track 3 Incorporation of nanoparticle albumin-bound (nab) paclitaxel in the treatment of breast cancer
Track 4 Proposed SWOG randomized Phase II trial of nab paclitaxel and sunitinib in locally advanced and inflammatory breast cancer
Track 5 Defining clinical trial endpoints in the investigation of anti-angiogenic agents
Track 6 Treatment of HER2-positive metastatic breast cancer

Track 7 Administration and side effects of lapatinib
Track 8 Lapatinib for HER2-positive CNS metastases
Track 9 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) trial
Track 10 Dose and schedule of capecitabine
Track 11 Clinical use of capecitabine/bevacizumab in the treatment of metastatic breast cancer
Track 12 Incorporation of the epothilone B analog ixabepilone and capecitabine into the treatment of breast cancer

Track 13 Role of adjuvant anthracyclines in patients with HER2-positive disease
Track 14 SWOG-S0307: A Phase III study of adjuvant bisphosphonates in Stage I to III breast cancer
Track 15 Z-FAST study: Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women receiving adjuvant letrozole

     
Robertson, MD John F R Robertson, MB,ChB, BSc, MD
Professor of Surgery
Head of Academic Division of Breast Surgery
University of Nottingham
City Hospital
Nottingham, United Kingdom		  
  Click here to download the entire interview  
Track 1 NEWEST (Neoadjuvant Endocrine therapy for Women with Estrogen-Sensitive Tumors) trial
Track 2 Background for the NEWEST trial
Track 3 Mechanism of action of fulvestrant
Track 4 Clinical use of fulvestrant with ovarian suppression for premenopausal women with metastatic breast cancer
Track 5 Ongoing clinical trials evaluating fulvestrant
Track 6 Clinical benefit of fulvestrant in HER2-positive metastatic breast cancer

Track 7 TAnDEM trial: Anastrozole with or without trastuzumab for ER-positive, HER2-positive metastatic disease
Track 8 Extended or delayed therapy with an aromatase inhibitor
Track 9 Biologic rationale for delayed recurrences in hormone receptor-positive breast cancer
Track 10 Immunologic and metabolic factors contributing to tumor growth

Track 11 Use of tumor markers for the early detection of breast cancer
Track 12 Rationale for the ineffectiveness of vaccines in breast cancer
     
  Tumor Panel Discussion  
Perez, MD Edith A Perez, MD
Professor of Medicine
Director, Cancer Clinical Study Unit
Director, Breast Cancer Program
Division of Hematology and Oncology
Mayo Clinic
Jacksonville, Florida		  
Robert, MD Nicholas J Robert, MD
Co-Chair, Breast Cancer Committee
US Oncology Research Network
Chairman, Cancer Committee
Cancer Center, Inova Fairfax Hospital
Fairfax, Virginia		  

Wolff, MD

Antonio C Wolff, MD
Associate Professor of Oncology
Breast Cancer Program
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
Baltimore, Maryland

  
  Click here to download the entire discussion  
Track 1 Case discussion: A woman with symptomatic, triple-negative metastatic breast cancer
Track 2 TBCRC-001: EGFR inhibition with cetuximab in triple-negative metastatic breast cancer
Track 3 Use of capecitabine in the management of taxane- and anthracycline-refractory, triple-negative metastatic disease
Track 4 Efficacy of bevacizumab with paclitaxel in patients previously treated with adjuvant paclitaxel
Track 5 Clinical use of bevacizumab with nab paclitaxel
Track 6 Clinical trials evaluating weekly nab paclitaxel

Track 7 Clinical use of nab paclitaxel
Track 8 RIBBON 2 trial of bevacizumab and chemotherapy in the second-line setting
Track 9 RIBBON 1 trial of bevacizumab and chemotherapy in the first-line setting
Track 10 Dramatic response to bevacizumab with paclitaxel in a patient with triple-negative metastatic breast cancer
Track 11 Continuation of bevacizumab at the time of disease progression
Track 12 Incorporating capecitabine into the treatment algorithm for a patient with triple-negative breast cancer
Track 13 Case discussion: A woman with hormone receptor-positive, HER2-negative metastatic breast cancer
Track 14 Clinical use of capecitabine for patients with hormone-refractory metastatic breast cancer
Track 15 Optimizing dose and schedule of capecitabine

Track 16 Halichondrin B analog for the treatment of breast cancer
Track 17 Clinical management of slowly progressive, refractory metastatic breast cancer
Track 18 Response to nab paclitaxel with bevacizumab in refractory disease
Track 19 Clinical trials for patients with heavily pretreated metastatic breast cancer
Track 20

Case discussion: A patient with triple-negative metastatic breast cancer treated with doxorubicin/
docetaxel (AT)
Track 21 Clinical use of AT for metastatic breast cancer
Track 22 Management of triple-negative disease